Saturday - February 28, 2026
Kidney Cancer Study Finds Belzutifan Plus Pembrolizumab Post-Surgery Helps Patients at High Risk for Relapse Stay Cancer-Free Longer
February 28, 2026
BOSTON, Massachusetts, Feb. 28 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Kidney Cancer Study Finds Belzutifan Plus Pembrolizumab Post-Surgery Helps Patients at High Risk for Relapse Stay Cancer-Free Longer

*

Dana-Farber Cancer Institute presents phase 3 LITESPARK-022 data at the 2026 ASCO Genitourinary Cancers Symposium

Patients with a common form of kidney cancer called . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products